Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis/Schering AG Re-Evaluating PTK/ZK Development Due To Low Probability Of Survival Benefit

This article was originally published in The Pink Sheet Daily

Executive Summary

Firms plan to reconsider NDA submission strategy after interim analysis of CONFIRM-2 trial suggests PTK/ZK 787 is unlikely to yield survival benefit in second-line metastatic colorectal cancer.

You may also be interested in...



Novartis Oncology President David Epstein: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

Novartis’ oncology chief discusses expectations for Tasigna and outlook for late-stage pipeline.

Novartis Oncology President David Epstein: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

Novartis’ oncology chief discusses expectations for Tasigna and outlook for late-stage pipeline.

Novartis/Schering AG's Vatalanib Efficacy Not CONFIRMed; Filing Delayed Until 2007

Colorectal cancer agent fails to meet primary endpoint of central radiology review-assessed progression-free survival in the CONFIRM-1 trial, Novartis says. The company expects data on overall survival for the agent, also known as PTK-ZK, to be available in the second half of 2006.

Topics

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel